Aligos Therapeutics in Partici –

SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (ALGS), a clinical-stage biopharmaceutical company focused on developing novel therapies to address unmet medical needs in viral and liver diseases , today announced that the company will participate in the new Metropolitan AntiViral Drug Accelerator (MAVDA) which recently received a three-year, $65,141,731 grant from the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Disease (NIAID)’s Antiviral Drug Discovery Centers (AViDD) Program for Pathogens of Pandemic Concern.

MAVDA was formed to address the urgent need to develop new antiviral treatments for SARS-CoV-2, its variants, other coronaviruses and viruses with pandemic potential. The group aims to leverage its collective expertise to discover, optimize and test small molecule antiviral drug candidates designed to fight target coronaviruses with a focus on SARS-CoV-2, as well as at least one additional RNA virus that has the potential to cause a pandemic. Ultimately, MAVDA participants aim to rapidly develop drugs that can be administered orally on an outpatient basis.

In addition to Aligos, MAVDA brings together academic and industry experts in virology and drug development from Rockefeller University, Columbia University, and Memorial Sloan-Kettering Cancer Center (MSK) in New York; the Hackensack Meridian Center for Discovery and Innovation (CDI) and Rutgers University in New Jersey; as well as Merck and the non-profit Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) through its industry partnership with Takeda.

“We are excited to join forces with other members of this consortium to address one of the key emerging healthcare needs: safe and broadly effective antiviral therapies that can help control the ongoing pandemic. and constantly evolving,” said Lawrence M. Blatt, Ph.D., MBA, President and CEO of Aligos Therapeutics. “Our potent and broad-acting SARS-CoV-2 inhibitor 3CLpro offers the potential to effectively inhibit the current group of circulating COVID-19 variants and is designed to inhibit future variants as well as other coronaviruses that may emerge. “

David Perlin, Ph.D., scientific director and senior vice president of the Hackensack Meridian CDI and professor at the Hackensack Meridian School of Medicine, will co-lead the MAVDA. Perlin noted, “I believe that in times of dire need, we must rely on the agility of academics and biotech companies to find and optimize solutions to difficult scientific problems, when we need the resources of the most major drug developers to make these solutions available to the public. public as soon as possible.

MAVDA Co-Director Charles Rice Ph.D., 2020 Nobel Laureate in Physiology or Medicine and Maurice R. and Corinne P. Greenberg Professor of Virology and Head of the Virology and Infectious Diseases Laboratory at Rockefeller University , added: “We are pleased that the medicinal chemistry and virology experts at Aligos are joining us in our search for more comprehensive solutions to the COVID-19 pandemic. Their work to date on a small molecule therapeutic against the coronavirus gives us a head start toward our group’s pandemic relief and preparedness goals.

MAVDA will undertake five collaborative projects focused on developing candidates that each target one of a validated set of eight molecular targets playing critical roles in the life cycle of SARS-CoV-2, including 3CLpro, the target of Aligos’ broad-spectrum coronavirus protease inhibitor, ALG-097558.

Aligos recently selected ALG-097558 to proceed to clinical development, for which the company expects to file a Phase 1 clinical trial application in the second half of 2022. To date, the candidate has shown superior potency compared to nirmatrelvir ( PF-07321332) against SARS-CoV-2 and multiple resistant variants in all cellular and biochemical assays tested to date. ALG-097558 is 7 to 20 times more active than nirmatrelvir, depending on the variant. ALG-097558 exhibits potent broad-spectrum activity against alpha and beta coronaviruses and is expected to retain potent activity against potential future SARS-CoV-2 variants. Projected effective doses of ALG-097558 can be achieved in humans without a ritonavir booster. The program is part of Aligos’ collaboration and license agreement with KU Leuven, including its Center for Drug Design and Discovery (CD3), a drug discovery unit and a KU Leuven investment fund. , and the Rega Institute for Medical Research.

About Aligos
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 with a mission to become a global leader in the treatment of viral infections and liver disease. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver disease to create targeted therapies for non-alcoholic steatohepatitis (NASH). Aligos’ strategy is to leverage its team’s deep expertise and decades of drug development experience in liver diseases, particularly viral hepatitis, to rapidly advance its portfolio of potentially best-in-class molecules. their category.

Forward-looking statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts may be deemed “forward-looking statements”, including , but not limited to, statements regarding Aligos’ SARS-CoV-2 3CLpro inhibitor offering the potential to effectively inhibit the current pool of circulating COVID-19 variants and being designed to inhibit future variants as well as other coronaviruses that may emerge; the company’s expectation to file a Phase 1 clinical trial application for ALG-097558 in the second half of 2022; ALG-097558 with potent broad-spectrum activity against alpha and beta coronaviruses, and the expectation that it will retain potent activity against potential future variants of SARS-CoV-2; and the projected effective doses of ALG-097558 being achieved in humans without a ritonavir booster. Forward-looking statements are generally, but not always, identified by the use of words such as “may”, “will”, “would”, “believe”, “intend”, “plan”, “anticipate”. , “estimates,” “expects” and other similar terms indicating future results. These forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties inherent in the drug development process, including the stage of clinical development of Aligos, the process for designing and conducting clinical trials, the processes for regulatory approval, timing of regulatory filings, challenges associated with manufacturing pharmaceutical products, Aligos’ ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of capital resources of Aligos to fund operations, dependence on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the global COVID-19 pandemic and the developing conflict between Russia and Ukraine. For a more detailed description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to Aligos’ business generally, see Aligos’ quarterly report on Form 10-Q filed with the Securities and Exchange Commission on May 4, 2022 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unforeseen events.

Media Contact
Amy Jobe, Ph.D.
LifeSci Communications
+1 315 879 8192
[email protected]

Contact Investor
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
[email protected]


Comments are closed.